Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial

• Published in: Swiss medical weekly 2016, Vol.146 (102), p.w14274-w14274
• Main Authors: Kallinikou, Zacharenia, Arroyo, Diego, Togni, Mario, Lehman, Sonja, Corpataux, Noé, Cook, Malica, Müller, Olivier, Baeriswyl, Gérard, Stauffer, Jean-Christophe, Goy, Jean-Jacques, Puricel, Serban-George, Cook, Stéphane
• Format: Article
• Language: English
• Subjects: Absorbable Implants; Aged; bioresorbable vascular scaffold; coronary artery disease; Coronary Artery Disease - pathology; Coronary Artery Disease - therapy; Coronary Restenosis; drug-eluting stent; Drug-Eluting Stents; Everolimus - therapeutic use; Female; Humans; Immunosuppressive Agents - therapeutic use; Male; Middle Aged; optical coherence tomography; Percutaneous Coronary Intervention; Single-Blind Method; Sirolimus - analogs & derivatives; Sirolimus - therapeutic use; Tissue Scaffolds; Tomography, Optical Coherence; Treatment Outcome
• ISSN: 1424-7860; 1424-3997
• DOI: 10.4414/smw.2016.14274

Head-to-head optical coherence tomography (OCT) data comparing metallic stents with bioresorbable vascular scaffolds (BVS) are lacking. This study assessed vascular healing at 9-month follow-up after implantation of everolimus- and biolimus-eluting stents (EES; BES) and everolimus-eluting BVS. OCT was performed in 74 patients enrolled in the EVERBIO II (NCT01711931) trial (23 with EES: 26 lesions, 7 625 struts; 23 with BES: 26 lesions, 6 140 struts; 28 with BVS: 33 lesions, 10 891 struts). OCT images were acquired using the pullback and nonocclusive flushing technique and analysed offline. BVS demonstrated fewer uncovered struts per patient (12 ± 27 [3.8 ± 8.4%] vs 59 ± 55 [21.8 ± 13.7%] in the EES&BES group, p